F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Estrogen Receptor-positive Breast Cancer|Progesterone Receptor-negative Breast Cancer|Progesterone Receptor-positive Breast Cancer|Recurrent Breast Cancer|Stage IV Breast Cancer
Interventions: RADIATION: F-18 16 alpha-fluoroestradiol|RADIATION: fludeoxyglucose F 18|PROCEDURE: positron emission tomography|PROCEDURE: positron emission tomography|PROCEDURE: computed tomography|OTHER: laboratory biomarker analysis
Sponsor: National Cancer Institute (NCI)